dations of the Kelkar Committee are contained in its Supplementary Report, copies of which are already available in the Parliament Library. The Govt. has accepted the following recommendations so far:

(i) Transfer of 4 drugs from category 1 to category 2;

(ii) Exclusion of 15 drugs from the purview of price control under DPCO, 1987;

(iii) The constitution of an inter-Ministerial committee for consideration of requests for exclusion of drugs from price control where the production of bulk drugs occurs from basic stage by process developed through indigenous Research and Development.

(b) As early as possible.

Price fixation of Dexamethasone based formulations

131. DR. (SHRIMATI) SAROJINI MAHISHI: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3005 given in the Rajya Sabha on the 5th December, 1988 and state :

(a) whether it is a fact that the stay from fixation of prices of Dexamethasone based formulations was granted only in favour of Merind;

(b) if so, when was this stay granted;

(c) whether it is a fact that Supreme Court vacated the stay;

(d) if so, when;

(e) whether his Ministry fixed the prices of formulations based on this drug after vacation of stay;

(f) if so, when and the prices fixed for various packs;

(g) whether it is a fact that apart from Marind there are other producers of formulations based on this drug;

(h) if so, the names of the leading producers, brand name and price fixed for each pack of each producer;

(i) when was the price fixed and at what price each is being sold on 31st March, 1989

(j) whether his Ministry worked out the overcharing of each company on these medicines; and

(k) if so, what are the details thereof?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Yes, Sir.

(b) The stay was granted on 25-8-1981.

(c) and (d) Yes, Sir. The Supreme Court delivered their judgement on 1st May, 1987.

(e) and (f) The details of prices fixed on 17-4-1989 for non-leader packs produced by M/s. Merind are given below Ceiling prices in respect of leader packs are being notified shortly.

Sl.No	Name of the formulation	Pack size	Price fixed by Court
1	Decadron Topical Cream	3.5 gm.	2.61
2	Decadron Eye/Ear Solution	2·5 ml vial	3.79

(g) Yes, Sir.

(h) to (k) The required details to the extent available will be collected and laid on the Table of the House.

Price Control on drugs

132. SHRI ASHOK NATH VERMA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Kelkar Committee reviewed the sales turn over of drugs in its supplementary report;

(b) if so, what are the names of drugs recommended for price decontrol on the basis of sales turn over of less than rupees fifty lacs;

(c) whether it is also a fact that his Ministry has not taken any action on these recommendations;

(d) if so, what are the details thereof;

(e) whether it is a fact that Kelkar Committee recommended for continuation of price control on certain drugs despite having sales turn over of less than rupees fifty lacs; and

(f) if so, the names of those drugs and special reasons for maintenance of price control?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Yes, Sir.

(b) The list is enclosed as Statement (*See* below). More details are given in the Supplementary Report of the Kelkar Committee copies of which are already available in the Parliament Library.

(c) to (f) The recommendations in this regard are yet to be examined and final decision taken.

Statement

Drugs having turn-over less than Rupees fifty lakhs in 1986.

Sl.	Name of the Bulk Drugs
1.	Amiloride
2.	Bephenium Hydroxy Napthoate
3.	Carbimazole
4.	Dehydroemetine
5.	Depamine
6.	Epinephrine
7.	Ethosuximide
8.	Ethionamide
9.	Flurazepam
10.	Glyceryl Trinitrate
11.	Heparin
12.	Hydralazine
13.	Hepatatis—B Vaccine
14.	Isoprenaline
15.	Nitrazepam
16.	Nitrofurantoin
17.	Primaquin
18.	Oxazepam
19.	Probenecid
20.	Protionamide
21.	Pentamidine
22.	Procainamide
23.	Quinidine
24.	Sulphadimidine